Medical Marijuana, Inc. Subsidiary Kannaway®’s Japanese Division Announces August 2020 as Best Revenue Month in Company History

SAN DIEGO, CA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --  (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Japanese division of its subsidiary had its best revenue month ever in Company history in July 2020.

“The hemp-derived cannabidiol (CBD) market in Asia has exploded over the past year and, despite a global pandemic, this market continues to gain new consumers who are eager to take part,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We are proud to be one of the pioneers in bringing CBD to Japan and look forward to accomplishing many more financial and operational milestones in this country and other Asian countries in the near future.”

China and Japan present a large opportunity for Kannaway® as, according to Prohibition Partners, they collectively account for about 90 percent of Asia’s CBD market. The CBD market in Asia is projected to be worth  by 2024.

“We are excited about our growth in Japan and look forward to continuing to develop the marketplace,” said Kannaway® CEO Blake Schroeder.

About Kannaway®

 is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.

About Medical Marijuana, Inc.

. Medical Marijuana, Inc. () is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by  and ; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including and . Medical Marijuana, Inc. was named a top CBD producer by . Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product  has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy. 

Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at  or by visiting . To see Medical Marijuana, Inc.’s corporate video, .

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

LEGAL DISCLOSURE

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations Contact:

Andrew Hard

Chief Executive Officer

CMW Media

P. 858-264-6600



 

Investor Relations Contact:

P. (858) 283-4016